- Home
- SILO vs VIVS Comparison
SILO vs VIVS Comparison
Compare SILO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- VIVS
- Stock Information
- Founded
- SILO 2010
- VIVS 2007
- Country
- SILO United States
- VIVS United States
- Employees
- SILO N/A
- VIVS N/A
- Industry
- SILO Apparel
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILO Consumer Discretionary
- VIVS Health Care
- Exchange
- SILO Nasdaq
- VIVS Nasdaq
- Market Cap
- SILO 3.1M
- VIVS 3.6M
- IPO Year
- SILO N/A
- VIVS N/A
- Fundamental
- Price
- SILO $0.58
- VIVS $1.84
- Analyst Decision
- SILO
- VIVS
- Analyst Count
- SILO 0
- VIVS 0
- Target Price
- SILO N/A
- VIVS N/A
- AVG Volume (30 Days)
- SILO 2.4M
- VIVS 71.5K
- Earning Date
- SILO 05-09-2025
- VIVS 06-13-2025
- Dividend Yield
- SILO N/A
- VIVS N/A
- EPS Growth
- SILO N/A
- VIVS N/A
- EPS
- SILO N/A
- VIVS N/A
- Revenue
- SILO $72,102.00
- VIVS $144,000.00
- Revenue This Year
- SILO $1.86
- VIVS $59.08
- Revenue Next Year
- SILO N/A
- VIVS $18.24
- P/E Ratio
- SILO N/A
- VIVS N/A
- Revenue Growth
- SILO N/A
- VIVS N/A
- 52 Week Low
- SILO $0.41
- VIVS $1.56
- 52 Week High
- SILO $4.50
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SILO 45.16
- VIVS N/A
- Support Level
- SILO $0.43
- VIVS N/A
- Resistance Level
- SILO $0.49
- VIVS N/A
- Average True Range (ATR)
- SILO 0.06
- VIVS 0.00
- MACD
- SILO 0.03
- VIVS 0.00
- Stochastic Oscillator
- SILO 45.03
- VIVS 0.00
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.